Trump administration to announce drug pricing deals

• Smaller drugmakers have been slow to join pricing deals, with only Astellas confirmed by earlier reports, as companies like Ionis Pharmaceuticals see limited financial incentive to participate
• The administration claims its broader drug pricing push could save $200 billion in federal and state spending over the next decade, though this figure is speculative
• Actual savings remain unclear as Medicaid already receives steep discounts under existing law, and most program beneficiaries pay little out of pocket for prescriptions

Summary: Trump Administration Announces New Drug Pricing Deals

The Trump administration is set to announce a new round of drug pricing agreements on August 31, with pharmaceutical companies including Bayer, Takeda, CSL, and several mid-size biotechs expected to participate. The initiative aims to reduce U.S. prescription drug costs, which currently run nearly three times higher than in other developed nations.

Key Details:

• White House event scheduled for 3 p.m. ET on Monday
• New deals follow previous agreements with major drugmakers including Pfizer, Eli Lilly, and Amgen
• Companies agree to "most-favored-nation" pricing, matching lower prices paid in other developed countries
• Participating drugmakers receive regulatory relief in exchange for price cuts

Participation Challenges:

Smaller and mid-sized pharmaceutical companies have been slow to join the program. Reuters previously reported limited financial incentive for smaller firms, with only Japan's Astellas confirming participation by the earlier deadline. Executives at companies like Ionis Pharmaceuticals cited minimal financial benefits.

Financial Impact Uncertain:

The actual savings for government and patients remain unclear. Medicaid already receives steep discounts under existing law, and most beneficiaries pay minimal out-of-pocket costs. While the administration claims its broader drug pricing initiative could save billions in federal and state spending over the next decade, these projections are speculative.

Political Context:

The White House has staged multiple high-profile events with pharmaceutical executives this year, positioning healthcare affordability as a priority ahead of midterm elections that will determine congressional control. Companies declining comment include Bayer, Takeda, and CSL.